←
Paul Kluetz640 posts
Paul Kluetz avatar

Paul Kluetz

@pkluetz

med onc, interested in trial design, endpoints and scientifically rigorous measurement of the patient experience- tweets and opinions are my own

◷ Joined December 2008▧ 7 Photos and videos
Paul Kluetz avatar
Paul Kluetz@pkluetz·27 Jun 2023

Please join if you can. Patient generated data to inform the tolerability of drug products… exploring single item overall side effect impact with some fantastic experts in the #PRO field

This tweet is unavailable

Paul Kluetz avatar
Paul Kluetz@pkluetz·5 Jun 2023

This session did a nice job hearing both sides of the story on early endpoints and accelerated approval in oncology. Kudos to @FDAOncology Angelo De Claro for his balanced perspective.

This tweet is unavailable

Paul Kluetz avatar
Paul Kluetz@pkluetz·10 Apr 2023

The ORISE fellowship program has been such a productive opportunity for early career scientists to work with FDA on applied research questions @FDAOncology @Meena_PharmD

This tweet is unavailable

Paul Kluetz avatar
Paul Kluetz@pkluetz·4 Apr 2023

Excited to kick off this year's great line up of @FDAOncology regulatory science sessions by moderating an #AACR23 panel on #DecentralizedTrials for #Oncology #ClinicalResearch. Looking forward to seeing everyone in Orlando! Session details here https://t.co/psHTMeONhj

AACR@AACR25 Mar 2023

Adaptations to the #COVID19 pandemic showed that decentralized oncology trials are feasible. On Sunday, April 16, @FDAOncology Deputy Director Paul Kluetz will moderate a panel discussion on how to make these changes permanent at #AACR23. https://t.co/ApHCIefJTn

Post attachment
pallavi mishra-kalyani avatar
⟳ Paul Kluetz retweeted
pallavi mishra-kalyani@pmishrakalyani·1 Feb 2023

Incredibly excited to share a very informative #FDA guidance on #externalcontrols hot off the presses! So proud to have led the #statistics effort on this one, in conjunction with colleagues across @US_FDA including @FDAOncology fda.gov/regulatory-informati…

Manju George MVSc PhD avatar
⟳ Paul Kluetz retweeted
Manju George MVSc PhD@manjuggm·27 Oct 2022

It was a wonderful experience to share my pt perspectives & learn at the @US_FDA Project FrontRunner Mini Symposium yesterday 👆explored moving #clinicaltrials with novel agents to earlier lines in St IV #CRC Lots of insightful discussions 👀forward to more new drugs for more pts

Post attachment
Donna Rivera avatar
⟳ Paul Kluetz retweeted
Donna Rivera@DrDonnaRivera·1 Jun 2022

Thankful to be @ASCO faculty for the 1st time at #ASCO22 with these incredible panelists ➡️ @DrEdKim @jillfeldman4 @LundJenny discussing methods to enhance patient centric clinical evidence generation across the continuum. #RCT #RWD Please join the discussion on June 5th!

ASCO@ASCO27 May 2022

#ASCO22 Education Session to focus on the role of real-world data in improving #clinicaltrials 📊💻 fal.cn/3oYTG #ASCODailyNews @DrEdKim @cityofhope @DrDonnaRivera @FDAOncology @LundJenny @uncpublichealth @jillfeldman4 @EGFRResisters #RWE

Donna Rivera avatar
⟳ Paul Kluetz retweeted
Donna Rivera@DrDonnaRivera·15 Apr 2022

🐊Really honored to be a #40GatorsUnder40! 🧡💙Abundant gratitude to my family, friends, & colleagues for your guidance and collaboration! 🧡💙 Thanks @ufalumni @UFPharmacy. Dream Big, Build Resilience, & Be Kind! Go out there and change the 🌎 #GoGators #GoGreater @FDAOncology

Congratulations to @DrDonnaRivera, associate director for pharmacoepidemiology in the Oncology Center of Excellence at the @US_FDA for being named to #40GatorsUnder40 class of 2022! She is a '12 PharmD and '14 MS graduate of @UFPharmacy. @DCGatorClub #GatorNation #GoGators

Post attachment